Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

Thyroid over-activity or hyperthyroidism constitutes a significant morbidity afflicting the world. The current medical practice of dose titration of anti-thyroid drug (ATD) treatment for hyperthyroidism is relatively archaic, being based on arbitrary and time-consuming trending of thyroid function that requires multiple clinic monitoring visits before an optimal dose is found. This prompts a re-examination into more deterministic and efficient treatment approaches in the present personalized medicine era. Our research project seeks to develop a personalized medicine model that facilitates optimal drug dosing via the titration regimen. We analysed 49 patients' data consisting of drug dosage, time period and serum free thyroxine (FT4). Ordinary differential equation modelling was applied to describe the dynamic behaviour of FT4 concentration. With each patient's data, an optimization model was developed to determine parameters of synthesis rate, decay rate and IC50. We derived the closed-form time- and dose-dependent solution which allowed explicit estimates of personalized predicted FT4. Our equation system involving time, drug dosage and FT4 can be solved for any variable provided the values of the other two are known. Compared against actual FT4 data within a tolerance, we demonstrated the feasibility of predicting the FT4 subsequent to any prescribed dose of ATD with favourable accuracy using the initial three to five patient-visits' data respectively. This proposed mathematical model may assist clinicians in rapid determination of optimal ATD doses within allowable prescription limits to achieve any desired FT4 within a specified treatment period to accelerate the attainment of euthyroid targets.

[1]  Victor M Montori,et al.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. , 2011, Thyroid : official journal of the American Thyroid Association.

[2]  Melvin Khee-Shing Leow,et al.  A Review of the Phenomenon of Hysteresis in the Hypothalamus–Pituitary–Thyroid Axis , 2016, Front. Endocrinol..

[3]  Melvin Khee-Shing Leow,et al.  The homeostatic set point of the hypothalamus-pituitary-thyroid axis – maximum curvature theory for personalized euthyroid targets , 2014, Theoretical Biology and Medical Modelling.

[4]  Nilay D Shah,et al.  Optimizing the Start Time of Statin Therapy for Patients with Diabetes , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[5]  L. Wartofsky,et al.  Graves' disease. , 2007, The Journal of clinical endocrinology and metabolism.

[6]  Melvin Khee-Shing Leow,et al.  Hypothalamus–Pituitary–Thyroid Feedback Control: Implications of Mathematical Modeling and Consequences for Thyrotropin (TSH) and Free Thyroxine (FT4) Reference Ranges , 2014, Bulletin of mathematical biology.

[7]  Melvin Khee-Shing Leow,et al.  A novel minimal mathematical model of the hypothalamus-pituitary-thyroid axis validated for individualized clinical applications. , 2014, Mathematical biosciences.

[8]  J. Franklyn Thyroid gland: Antithyroid therapy—best choice of drug and dose , 2009, Nature Reviews Endocrinology.

[9]  S. Ratanachaiyavong,et al.  Immunosuppressive effects of antithyroid drugs. , 1985, Clinics in endocrinology and metabolism.

[10]  S. Ratanachaiyavong,et al.  7 Immunosuppressive effects of antithyroid drugs , 1985 .

[11]  A. Avenell,et al.  Antithyroid drug regimen for treating Graves' hyperthyroidism. , 2005, The Cochrane database of systematic reviews.

[12]  Melvin Khee-Shing Leow,et al.  General Error Analysis in the Relationship between Free Thyroxine and Thyrotropin and Its Clinical Relevance , 2013, Comput. Math. Methods Medicine.

[13]  M. Leow,et al.  Changes in Hepatic TRβ Protein Expression, Lipogenic Gene Expression, and Long-Chain Acylcarnitine Levels During Chronic Hyperthyroidism and Triiodothyronine Withdrawal in a Mouse Model. , 2017, Thyroid : official journal of the American Thyroid Association.

[14]  O. Ukoumunne,et al.  Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves’ disease: a retrospective observational study , 2014, Clinical endocrinology.

[15]  Judit Zsuga,et al.  The Hill equation and the origin of quantitative pharmacology , 2012 .

[16]  R. Volpe Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review. , 1994, Thyroid : official journal of the American Thyroid Association.

[17]  S. Doi,et al.  A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism , 2001, BMC nuclear medicine.

[18]  P. Laurberg Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? , 2006, European journal of endocrinology.

[19]  Stephen P. Boyd,et al.  Convex Optimization , 2004, Algorithms and Theory of Computation Handbook.

[20]  M. Leow,et al.  Desensitization and Incomplete Recovery of Hepatic Target Genes After Chronic Thyroid Hormone Treatment and Withdrawal in Male Adult Mice. , 2016, Endocrinology.

[21]  M. Leow,et al.  Immune manipulation for Graves' disease: re-exploring an unfulfilled promise with modern translational research. , 2012, European journal of internal medicine.

[22]  H. J. Arnold Introduction to the Practice of Statistics , 1990 .

[23]  Douglas M. Bates,et al.  Nonlinear Regression Analysis and Its Applications , 1988 .

[24]  Anahita Khojandi,et al.  From Data to Improved Decisions: Operations Research in Healthcare Delivery , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.